

Supplemental Table 1 Baseline Characteristics of Unmatched Population

Characteristic	Treatment Start 0-13 d			Treatment Start 0-6 d		
	0-6 d	7-13 d	P Value	0-3 d	4-6 d	P Value
Patients, n	9688	1431		8296	1392	
Age, y						
Mean	65.6 ± 9.9	65.6 ± 9.9	.74	65.7 ± 9.9	65.3 ± 10	.78
Median (range)	66 (19-90)	66 (32-90)	.62	66 (19-90)	66 (32-90)	.66
RT duration, d						
Mean	52.1 ± 5.1	52.4 ± 5.1	.012	64.7 ± 3.6	65.0 ± 3.7	.27
Median (range)	52 (42-64)	52 (42-64)	.015	64.8 (59.4-74)	65.0 (59.4-74)	.26
RT dose, Gy						
Mean	64.9 ± 3.6	64.8 ± 3.6	.14	52 ± 5.0	52.6 ± 5.2	.53
Median (range)	64.8 (59.4-74.0)	64.8 (59.4-74.0)	.15	51 (42-64)	52 (42-64)	.40
Race			.02			.78
White	8477 (87.5)	1221 (85.3)		7276 (87.7)	1201 (86.3)	
Nonwhite	1211 (12.5)	210 (14.7)		1020 (12.3)	191 (13.7)	
Gender			.76			.60
Female	3878 (40)	579 (40.5)		3358 (40.5)	520 (37.4)	
Male	5810 (60)	852 (59.5)		4938 (59.5)	872 (62.6)	
Stage			.40			.98
II	21 (0.2)	1 (0.1)		18 (0.2)	3 (0.2)	
IIA	190 (2)	22 (1.5)		164 (2)	26 (1.9)	
IIB	734 (7.6)	97 (6.8)		640 (7.7)	94 (6.8)	
III	72 (0.7)	7 (0.5)		57 (0.7)	15 (1.1)	
IIIA	4694 (48.5)	703 (49.1)		4046 (48.8)	648 (46.6)	
IIIB	3977 (41.1)	601 (42)		3371 (40.6)	606 (43.5)	
CD score			.12			.98
0	6260 (64.6)	888 (62)		5369 (64.7)	891 (64)	
1	2506 (22.9)	406 (28.4)		2159 (26)	347 (24.9)	
≥2	922 (9.5)	137 (9.6)		768 (9.3)	154 (11.1)	
Insurance			.99			.90
Private	3113 (32.1)	463 (32.4)		2673 (32.3)	440 (31.6)	
None	332 (3.4)	50 (3.5)		268 (3.2)	64 (4.6)	
Government	6138 (63.4)	903 (63.1)		5261 (63.4)	877 (63)	
Unknown	105 (1.1)	15 (1.1)		94 (1.2)	11 (0.8)	
Histologic type			.18			.99
Adenocarcinoma	2815 (29.1)	386 (27)		2465 (29.7)	350 (25.1)	
SCC	4202 (43.4)	618 (43.2)		3557 (42.9)	645 (46.3)	
Bronchoalveolar	49 (0.5)	5 (0.4)		42 (0.5)	7 (0.5)	
Large cell	303 (3.1)	56 (3.9)		265 (3.2)	38 (2.7)	
Other	2319 (23.9)	366 (25.6)		1967 (23.7)	352 (25.3)	
Income			.0001			.78
>\$35,000	5876 (60.6)	792 (55.4)		5073 (61.2)	803 (57.7)	
≤\$35,000	3812 (39.4)	639 (44.6)		3223 (38.8)	589 (42.3)	
Area			.43			.24
Urban	9387 (96.9)	1392 (97.3)		8041 (96.9)	1346 (96.7)	
Rural	301 (3.1)	39 (2.7)		255 (3.1)	46 (3.3)	
Distance, miles			.078			.051
0-49.9	9070 (93.6)	1357 (94.8)		7751 (93.4)	1319 (94.8)	
≥50	618 (6.4)	74 (5.2)		545 (6.6)	73 (5.2)	

Asynchronous Chemoradiation and Lung Cancer

Supplemental Table 1 Continued

Characteristic	Treatment Start 0-13 d			Treatment Start 0-6 d		
	0-6 d	7-13 d	P Value	0-3 d	4-6 d	P Value
Facility type			.20			.77
Academic	1872 (19.3)	256 (17.9)		1607 (19.4)	256 (19)	
Other	7816 (80.7)	1175 (82.1)		6689 (80.6)	1127 (81)	
Location			<.0001			.99
Northeast	1735 (18)	256 (18)		1475 (17.9)	260 (18.7)	
Central	3565 (37)	447 (31.3)		3108 (37.7)	457 (32.9)	
South	3360 (34.8)	591 (41.4)		2815 (34.1)	545 (39.3)	
West	982 (10.2)	132 (9.3)		856 (10.4)	126 (9.1)	

Data presented as n (%), unless noted otherwise.

Abbreviations: CD = Charlson/Deyo (comorbidity); RT = radiation therapy; SCC = squamous cell carcinoma.